Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.

Bioorg Med Chem Lett

Department of Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.

Published: April 2003

A series of imidazole-containing biphenyls was prepared and evaluated in vitro for inhibition of FTase and cellular Ras processing. Several of these analogues, such as 21, are potent inhibitors of FTase (<1nM), FTase/GGTase selective (>300-fold) and cellularly active (

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(03)00096-9DOI Listing

Publication Analysis

Top Keywords

novel selective
4
selective imidazole-containing
4
imidazole-containing biphenyl
4
biphenyl inhibitors
4
inhibitors protein
4
protein farnesyltransferase
4
farnesyltransferase series
4
series imidazole-containing
4
imidazole-containing biphenyls
4
biphenyls prepared
4

Similar Publications

Modernizing power systems into smart grids has introduced numerous benefits, including enhanced efficiency, reliability, and integration of renewable energy sources. However, this advancement has also increased vulnerability to cyber threats, particularly False Data Injection Attacks (FDIAs). Traditional Intrusion Detection Systems (IDS) often fall short in identifying sophisticated FDIAs due to their reliance on predefined rules and signatures.

View Article and Find Full Text PDF

Using machine learning to forecast peak health care service demand in real-time during the 2022-23 winter season: A pilot in England, UK.

PLoS One

January 2025

Real-time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham, United Kingdom.

During winter months, there is increased pressure on health care systems in temperature climates due to seasonal increases in respiratory illnesses. Providing real-time short-term forecasts of the demand for health care services helps managers plan their services. During the Winter of 2022-23 we piloted a new forecasting pipeline, using existing surveillance indicators which are sensitive to increases in respiratory syncytial virus (RSV).

View Article and Find Full Text PDF

This case report highlights a potential vaccine safety concern associated with the Pseudorabies virus (PRV) live vaccine, which warrants further investigation for comprehensive understanding. Vaccine-induced immune thrombotic thrombocytopenia (VITT), a novel syndrome of adverse events following adenovirus vector COVID-19 vaccines, was observed after vaccination with Zoetis PR-VAC PLUS. This led to a 100% morbidity and high mortality among PRV-free Danish purebred pigs from Danish Genetics Co.

View Article and Find Full Text PDF

Tailoring molecular diffusion in core-shell zeolite imidazolate framework composites realizes efficient kinetic separation of xylene isomers.

Angew Chem Int Ed Engl

January 2025

Zhejiang University, Key Laboratory of Biomass Chemical Engineering of the Ministry of Education, College of Chemical and Biological Engineering, 866 Yuhangtang Road, Xihu District, hangzhou City, 310058, Hangzhou, CHINA.

The separation of xylene isomers is a critical and energy-intensive process in the petrochemical industry, primarily due to their closely similar molecular structures and boiling points. In this work, we report the synthesis and application of a novel core-shell zeolitic imidazolate framework (ZIF) composite, ZIF-65@ZIF-67, designed to significantly enhance the kinetic separation of xylene isomers through a synergistic "shell-gated diffusion and core-facilitated transport" strategy. The external ZIF-67 shell selectively restricts the diffusion of larger isomers (MX and OX), while the internal ZIF-65 core accelerates the diffusion of PX, thereby amplifying the diffusion differences among the isomers.

View Article and Find Full Text PDF

Introduction: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX.

Methods: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!